Sanara MedTech Inc.: receives FTC second request on MiMedx merger

What happened

• The filing says Sanara MedTech Inc entered into an Agreement and Plan of Merger with MiMedx Group, Inc. and Mustang Merger Sub, Inc., under which Mustang Merger Sub will be merged with and into the Company, with the Company surviving the merger as a wholly owned subsidiary of MiMedx.
• On Oct 15, 2026, the Company and MiMedx each received a request for additional information and documentary materials (a "Second Request") from the Federal Trade Commission in connection with the FTC’s review of the merger.

Key details

• The Second Request extends the waiting period imposed by the Hart-Scott-Rodino Antitrust Improvements Act until 30 days after the parties have substantially complied with the Second Request, unless that period is extended voluntarily or terminated earlier by the FTC.
• Completion of the merger remains subject to the expiration or termination of the waiting period under the HSR Act and the satisfaction or waiver of other closing conditions specified in the Merger Agreement.
• MiMedx filed a registration statement on Form S-4 that includes a proxy statement of Sanara and constitutes a prospectus of MiMedx; the filing says the final prospectus has been mailed to Sanara stockholders and that related documents are available on the SEC website, Sanara’s investor relations site, and MiMedx’s investor site.
• The filing includes forward-looking statements about timing for completion, expected benefits and financial projections and references risk factors in Sanara’s Form 10-K for the year ended Dec 31, 2025 and Form 10-Q for the quarter ended Jun 30, 2026.

Why it may matter

• This report was filed as an Item 8.01 "Other events" and covers the receipt of an FTC Second Request and the effect on the HSR Act waiting period for the proposed merger.
• A filing does not show why the insider traded or why the company acted.